peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical financial reporting dates

15 Jan 2015, 08:00
Regulatory information

Hansa Medical proceeds to releasing financial reports quarterly. The following dates have been scheduled for financial reporting during 2015:

Year-end release 2014, February 13, 2015
Annual report 2014, March 2, 2015
Interim report January – March 2015, April 16, 2015
Annual General Meeting 2015, April 16, 2015
Interim report January – June 2015, August 25, 2015
Interim report January – September 2015, October 28, 2015

For further information, please contact:
Hansa Medical AB
Fredrik Lindgren, President and CEO
Mobile: 46 705 61 61 77

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on NASDAQ First North in Stockholm with Remium Nordic AB as Certified Adviser. Major shareholders are Farstorps Gård AB and Nexttobe AB.